| Terminated | A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participan Ovarian Neoplasms | Phase 2 | 2022-04-14 |
| Terminated | Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Partici Ovarian Neoplasms | Phase 2 | 2019-10-03 |
| Active Not Recruiting | A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Part Neoplasms | Phase 3 | 2019-07-18 |
| Completed | A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cance Ovarian Neoplasms | Phase 2 | 2018-11-15 |
| Completed | Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurren Ovarian Neoplasm | Phase 2 | 2018-11-15 |
| Active Not Recruiting | A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma | Phase 3 | 2018-10-11 |
| Completed | Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Neoplasms, Breast | Phase 1 | 2018-04-12 |
| Completed | Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients Ovarian Neoplasms, Neoplasms, Solid Tumor | Phase 1 | 2018-02-20 |
| Completed | A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Can Ovarian Neoplasms | Phase 2 | 2017-12-12 |
| Completed | Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Nira Neoplasms | Phase 1 | 2017-12-04 |
| Completed | Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 Neoplasms, Metastatic Cancer, Advanced Cancer | Phase 1 | 2017-10-12 |
| Completed | Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Ce Neoplasms | Phase 2 | 2017-09-29 |
| Completed | Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumo Neoplasms | Phase 1 | 2017-08-08 |
| Active Not Recruiting | A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Ovarian Neoplasms | Phase 3 | 2016-07-11 |
| Active Not Recruiting | A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) Neoplasms | Phase 1 | 2016-07-08 |
| Completed | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer Neoplasms, Triple Negative Breast Cancer, Ovarian Cancer | Phase 1 / Phase 2 | 2016-04-15 |
| Active Not Recruiting | Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Ad Neoplasms | Phase 1 | 2016-03-07 |
| Completed | An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Chemotherapy-induced Nausea and Vomiting | Phase 1 | 2015-05-01 |
| Completed | A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Reg Ovarian Neoplasms, Ovarian Cancer | Phase 2 | 2015-03-23 |
| Completed | Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects Cancer | Phase 1 | 2015-02-01 |
| Completed | A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolap Chemotherapy-induced Nausea and Vomiting | Phase 1 | 2015-01-01 |
| Completed | An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant Chemotherapy-induced Nausea and Vomiting | Phase 1 | 2014-09-01 |
| Terminated | A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Bre Neoplasms, Breast, Carcinoma of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 3 | 2014-02-25 |
| Completed | A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer Ovarian Neoplasms, Platinum Sensitive Ovarian Cancer | Phase 3 | 2013-06-21 |
| Completed | A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors, Lymphomas | Phase 1 / Phase 2 | 2012-10-01 |
| Completed | Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Che Chemotherapy-induced Nausea and Vomiting | Phase 3 | 2012-02-01 |
| Completed | Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Ch Chemotherapy-induced Nausea and Vomiting | Phase 3 | 2012-02-01 |
| Completed | Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Che Chemotherapy-induced Nausea and Vomiting | Phase 3 | 2012-02-01 |
| Withdrawn | A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002) Lymphoma, Mantle-Cell | Phase 2 | 2010-12-01 |
| Terminated | MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ova Ovarian Cancer | Phase 1 | 2010-11-01 |
| Terminated | A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-48 Cancer: Solid Tumors | Phase 1 | 2010-07-01 |
| Completed | A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) Solid Tumors, Chronic Lymphocytic Leukemia, T-cell-prolymphocytic Leukemia | Phase 1 | 2008-09-01 |
| Approved For Marketing | Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer Recurrent Ovarian Cancer | — | — |